Your browser is no longer supported. Please, upgrade your browser.
CPRX [NASD]
Catalyst Pharmaceuticals, Inc.
Index- P/E6.09 EPS (ttm)0.70 Insider Own7.00% Shs Outstand103.70M Perf Week-9.30%
Market Cap455.64M Forward P/E9.33 EPS next Y0.46 Insider Trans-0.05% Shs Float96.41M Perf Month13.79%
Income75.00M PEG- EPS next Q0.09 Inst Own66.20% Short Float9.91% Perf Quarter23.28%
Sales119.10M P/S3.83 EPS this Y134.70% Inst Trans-4.24% Short Ratio5.43 Perf Half Y30.00%
Book/sh1.64 P/B2.62 EPS next Y26.37% ROA48.70% Target Price7.50 Perf Year-2.72%
Cash/sh1.32 P/C3.25 EPS next 5Y- ROE55.80% 52W Range2.88 - 5.19 Perf YTD28.44%
Dividend- P/FCF- EPS past 5Y37.00% ROI43.90% 52W High-16.67% Beta1.32
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin85.70% 52W Low50.43% ATR0.23
Employees74 Current Ratio7.00 Sales Q/Q3.00% Oper. Margin34.60% RSI (14)51.07 Volatility4.05% 5.82%
OptionableYes Debt/Eq0.00 EPS Q/Q45.30% Profit Margin63.00% Rel Volume0.36 Prev Close4.29
ShortableYes LT Debt/Eq0.00 EarningsMar 15 AMC Payout0.00% Avg Volume1.76M Price4.32
Recom2.00 SMA20-1.41% SMA503.36% SMA20014.23% Volume504,950 Change0.82%
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-07-18Resumed Piper Jaffray Overweight
Oct-05-16Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16Downgrade Piper Jaffray Overweight → Neutral $6 → $1
Sep-30-14Reiterated ROTH Capital Buy $5 → $6
Sep-16-14Reiterated ROTH Capital Buy $3.50 → $5
Sep-15-14Reiterated H.C. Wainwright Buy $5 → $13
Oct-21-13Reiterated Aegis Capital Buy $4 → $5.50
Sep-24-13Initiated Maxim Group Buy $4
Sep-06-13Reiterated Aegis Capital Buy $3.50 → $4
Apr-18-13Initiated Aegis Capital Buy $2.50
Aug-27-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $3.70
Oct-01-09Upgrade Merriman Sell → Neutral
May-29-09Downgrade Merriman Curhan Ford Buy → Sell
May-29-09Downgrade Hapoalim Neutral → Underperform
Dec-15-08Initiated Merriman Curhan Ford Buy
Nov-28-07Initiated Rodman & Renshaw Mkt Outperform $9
Jan-31-07Initiated Stifel Nicolaus Buy $9
Jan-05-07Initiated First Albany Buy $10
Apr-05-21 01:03AM  
Mar-22-21 08:03AM  
Mar-21-21 04:42AM  
Mar-18-21 06:02PM  
Mar-16-21 10:38AM  
06:30AM  
Mar-15-21 06:45PM  
05:26PM  
Mar-08-21 12:30PM  
Mar-04-21 11:00AM  
Feb-22-21 08:03AM  
Feb-13-21 02:41AM  
Jan-28-21 10:44AM  
Jan-06-21 08:07AM  
Dec-30-20 01:42AM  
Dec-16-20 12:32PM  
Dec-09-20 11:30AM  
Nov-15-20 07:50AM  
Nov-11-20 05:44AM  
Nov-09-20 06:35PM  
05:20PM  
Nov-02-20 08:03AM  
Oct-28-20 10:33AM  
Oct-19-20 06:03AM  
Oct-08-20 07:32AM  
Oct-06-20 05:46PM  
11:15AM  
10:01AM  
Sep-29-20 04:40PM  
Sep-09-20 11:30AM  
Sep-08-20 11:00AM  
Aug-26-20 09:40AM  
Aug-24-20 09:05AM  
Aug-18-20 08:03AM  
Aug-16-20 09:12AM  
Aug-14-20 10:30AM  
Aug-11-20 09:27AM  
06:00AM  
Aug-10-20 05:55PM  
04:15PM  
Aug-07-20 11:11AM  
Aug-06-20 08:03AM  
Aug-03-20 04:15PM  
08:03AM  
Jul-31-20 11:10AM  
Jul-29-20 12:33PM  
Jul-28-20 11:11AM  
Jul-16-20 12:44PM  
Jul-14-20 12:55PM  
Jul-10-20 01:48PM  
Jul-09-20 03:03PM  
Jun-23-20 08:03AM  
Jun-22-20 10:49AM  
Jun-18-20 09:12PM  
Jun-10-20 11:30AM  
Jun-01-20 08:03AM  
May-17-20 08:31AM  
May-14-20 08:18AM  
May-11-20 07:25PM  
04:17PM  
May-04-20 08:03AM  
Apr-29-20 10:02AM  
05:33AM  
Apr-15-20 11:30AM  
Apr-08-20 06:00AM  
Apr-06-20 09:04AM  
Mar-17-20 06:30AM  
Mar-16-20 05:26PM  
Mar-10-20 08:03AM  
Mar-09-20 12:30PM  
Feb-27-20 08:03AM  
Feb-26-20 08:03AM  
Feb-24-20 09:42AM  
Feb-06-20 08:03AM  
Feb-04-20 08:02AM  
Jan-15-20 08:58AM  
Jan-07-20 09:17AM  
Jan-06-20 08:03AM  
Jan-03-20 05:15PM  
Dec-24-19 06:33AM  
Dec-13-19 02:45PM  
Dec-12-19 11:30AM  
Nov-29-19 09:39AM  
Nov-26-19 08:03AM  
Nov-16-19 08:15AM  
Nov-13-19 02:05PM  
09:05AM  
Nov-12-19 06:26PM  
04:39PM  
Nov-11-19 05:21PM  
Nov-08-19 10:33AM  
Nov-07-19 06:15PM  
Nov-01-19 12:32PM  
Oct-31-19 10:45AM  
08:03AM  
Oct-30-19 06:03AM  
Oct-29-19 03:16PM  
09:46AM  
Oct-25-19 08:38AM  
Oct-19-19 09:56PM  
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGENITO GARYChief Medical OfficerDec 22Sale3.453,66812,64410,998Dec 28 04:47 PM
O'Keeffe Charles BDirectorSep 30Buy2.997,00020,930560,376Sep 30 02:23 PM
MCENANY PATRICK JPresident and CEOSep 30Buy2.9715,00044,5504,787,693Sep 30 10:55 AM